Genmab — September 2019
-
At det er påfaldende, at USA falder ned under det danske tradingrange.
-
Nyheder= Analytikerkommentarer
-
Kan man ikke shorte de to instrumenter hver for sig?
-
Jeg meget glad, men også nysgerrig på mekanismerne i markedet. Dem får jeg spørgsmål om i mange sammenhænge.
-
By Garvins lille survey viste: The Crowd has predicted that ofatumumab will reduce the ARR (relative annualised relapse rate) and CDP (confirmed disability progression) compared to teriflunomide by 41.2% (interquartile range=34.0-49.0%) and 29.3% (interquartile range=20.0-37.3%), respectively.
-
Link til ovenstående https://multiple-sclerosis-research.org/2019/09/results-time/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind